Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — Stella

Home/Acute Leukemia/

View on ClinicalTrials.gov

Recruiting

Back to Acute Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Key details

Phase

Safety & dosing

Sponsor

Masonic Cancer Center, University of Minnesota

Enrollment target

~300 participants

Started

March 2018

Primary completion

June 2026

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.